scholarly journals IN VITRO DISSOLUTION AND PILOT PHARMACOKINETIC STUDIES OF ACETYLSALICYLIC ACID FROM AN ORALLY DISINTEGRATING TABLET FORMULATION OF LOW-DOSE ASPIRIN

2011 ◽  
Vol 2 (2) ◽  
pp. 72-77
Author(s):  
YOUSIF ROJEAB ◽  
◽  
SHANE MARTIN B ◽  
ROBIN WHITE ◽  
SUSAN MONTENERY ◽  
...  
2009 ◽  
Vol 24 (10) ◽  
pp. 2447-2450 ◽  
Author(s):  
M. J. Lambers ◽  
E. Groeneveld ◽  
D. A. Hoozemans ◽  
R. Schats ◽  
R. Homburg ◽  
...  

2009 ◽  
Vol 101 (04) ◽  
pp. 687-690 ◽  
Author(s):  
Caterina Pettinella ◽  
Mario Romano ◽  
Liborio Stuppia ◽  
Francesca Santilli ◽  
Rossella Liani ◽  
...  

SummaryCOX-1 polymorphism C50T, in complete linkage disequilibrium with the other polymorphism A-842G, has been depicted as a determinant of pharmacological response to aspirin treatment. Whether these polymorphisms exert an effect on response to aspirin both in vitro and ex vivo is still controversial. We geno-typed a population of 148 healthy individuals for the C50T/A-842G haplotype. Thirty of them underwent low-dose aspirin (100 mg daily) treatment for four weeks and were followed up for seven days after withdrawal. In this subgroup, we evaluated the thromboxane-dependence of biochemical and functional indexes used to monitor the antiplatelet effect of low-dose aspirin. Among the 148 subjects studied, 10 were heterozygous for the C50T/A-842G haplotype (6.7%) and only one was homozygous for the 50T/-842G haplotype (0.67%). In the group on low-dose aspirin, serum thromboxane (TX) B2 as well as urinary 11-dehydro-TXB2 and arachidonic acid (AA)-induced aggregation were similarly suppressed in carriers and non-carriers of the 50T/-842G haplotype, with an increase until basal levels of all the parameters within seven days after withdrawal. We found no relationship between the 50T/-842G haplotype and the so-called phenomenon of aspirin resistance. Platelet cyclooxygenase activity, as reflected by serum TXB2, was uniformly and persistently suppressed by low-dose aspirin in both carriers and non carriers of these polymorphisms.


2008 ◽  
Vol 90 ◽  
pp. S211
Author(s):  
M.J. Lambers ◽  
E. Groeneveld ◽  
D.A. Hoozemans ◽  
R. Schats ◽  
C.B. Lambalk ◽  
...  

2017 ◽  
Vol 33 (2) ◽  
pp. 296-299 ◽  
Author(s):  
Palika Datta ◽  
Kathleen Rewers-Felkins ◽  
Raja Reddy Kallem ◽  
Teresa Baker ◽  
Thomas W. Hale

Background: Aspirin has antipyretic and anti-inflammatory properties and is frequently used by pregnant and lactating women. However, its transfer in human milk when administered at low dose has not been reported. Research aim: This study aimed to evaluate the transfer of acetylsalicylic acid and its metabolite, salicylic acid, into human milk following the use of low dose aspirin. Methods: In this study, milk samples were collected at 0, 1, 2, 4, 8, 12, and 24 hours from seven breastfeeding women after a steady-state daily dose of 81 mg of aspirin. Milk levels of acetylsalicylic acid and salicylic acid were determined by liquid chromatography–tandem mass spectrometry. Results: Acetylsalicylic acid levels were below the limit of quantification (0.61 ng/ml) in all the milk samples, whereas salicylic acid was detected at very low concentrations. The average concentration of salicylic acid observed was 24 ng/ml and the estimated relative infant dose was 0.4%. Conclusion: Acetylsalicylic acid transfer into milk is so low that it is undetectable even by highly sophisticated methodology. Salicylic acid does appear in the human milk in comparatively low amounts, which are probably subclinical in infants. Thus, the daily use of an 81-mg dose of aspirin should be considered safe during lactation.


1994 ◽  
Vol 74 (7) ◽  
pp. 720-723 ◽  
Author(s):  
Salim F. Dabaghi ◽  
Suraj G. Kamat ◽  
John Payne ◽  
Gary F. Marks ◽  
Robert Roberts ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document